Clearance of interstitial fluid (ISF) and CSF (CLIC) group-part of Vascular Professional Interest Area (PIA), updates in 2022-2023. Cerebrovascular disease and the failure of elimination of Amyloid-β from the brain and retina with age and Alzheimer's dise
| Publication Type | Review |
| Authors | Kelly L, Brown C, Michalik D, Hawkes C, Aldea R, Agarwal N, Salib R, Alzetani A, Ethell D, Counts S, de Leon M, Fossati S, Koronyo-Hamaoui M, Piazza F, Rich S, Wolters F, Snyder H, Ismail O, Elahi F, Proulx S, Verma A, Wunderlich H, Haack M, Dodart J, Mazer N, Carare R |
| Journal | Alzheimers Dement |
| Volume | 20 |
| Issue | 2 |
| Pagination | 1421-1435 |
| Date Published | 10/28/2023 |
| ISSN | 1552-5279 |
| Keywords | Alzheimer Disease, Cerebral Amyloid Angiopathy, Cerebrovascular Disorders |
| Abstract | This editorial summarizes advances from the Clearance of Interstitial Fluid and Cerebrospinal Fluid (CLIC) group, within the Vascular Professional Interest Area (PIA) of the Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART). The overarching objectives of the CLIC group are to: (1) understand the age-related physiology changes that underlie impaired clearance of interstitial fluid (ISF) and cerebrospinal fluid (CSF) (CLIC); (2) understand the cellular and molecular mechanisms underlying intramural periarterial drainage (IPAD) in the brain; (3) establish novel diagnostic tests for Alzheimer's disease (AD), cerebral amyloid angiopathy (CAA), retinal amyloid vasculopathy, amyloid-related imaging abnormalities (ARIA) of spontaneous and iatrogenic CAA-related inflammation (CAA-ri), and vasomotion; and (4) establish novel therapies that facilitate IPAD to eliminate amyloid β (Aβ) from the aging brain and retina, to prevent or reduce AD and CAA pathology and ARIA side events associated with AD immunotherapy. |
| DOI | 10.1002/alz.13512 |
| PubMed ID | 37897797 |
| PubMed Central ID | PMC10917045 |